+ [于无声处见新篇的中国石油](https://xueqiu.com/3350642636/337103034)
+ [白酒行业龙头成长因子解构](https://xueqiu.com/4465952737/337086376)
+ [2025年5月报——面向未来的情绪价值](https://xueqiu.com/9743713791/337107955)
+ [普适的投资规律](https://xueqiu.com/7913104177/337123277)
+ [中远海控年度股东会](https://xueqiu.com/9827277793/336768782)
+ [美的集团股东大会：增长要接力，股东回报会继续提高](https://xueqiu.com/3605089580/337076631)
+ [高分红A股“七朵金花”VS成长型港股“七朵金花”，那个更值得投资？](https://xueqiu.com/7271353740/337128347)
+ [但有路可上，更高人也行：简析HARMONi顶线数据](https://xueqiu.com/2693678800/337053114)
+ [中微业绩会详聊](https://xueqiu.com/1633174482/337012656)
+ [创新药投资的冰与火之歌](https://xueqiu.com/9742512811/337068656)
+ [投研理念｜如何通俗易懂的看懂三张财务报表？](https://xueqiu.com/3199838879/337050641)
+ [为什么你卖出就涨？买入就跌](https://xueqiu.com/2093337947/337055951)
+ [写在成都银行股价即将站上净资产上方之际](https://xueqiu.com/2466842102/337016106)
+ [一文看懂稳定币的背景以及最佳投资方案](https://xueqiu.com/8983534016/337069397)
+ [Summit Therapeutics判断其 PD-1/VEGF 双特异抗体 ivonescimab 是否能获得 美国FDA批准-专业解答](https://xueqiu.com/6540058727/337070020)
+ [国电电力的净利润：扣非还是归母？](https://xueqiu.com/3203323063/336850044)
+ [拼多多25Q1季度跟踪点评](https://xueqiu.com/3452146899/336960020)
+ [老窖不是昔日阿蒙](https://xueqiu.com/7913104177/336916726)
+ [再聊聊拼多多](https://xueqiu.com/2103206506/336996822)
+ [关于投资的思考：关于水电的几个核心问题！](https://xueqiu.com/3237139935/336918996)
+ [三维度冷眼观察长江电力：不便宜了，不便宜了，不便宜了！](https://xueqiu.com/9363345092/337203777)
+ [2025年医药创新药行情分析](https://xueqiu.com/4777061674/337185060)
+ [五粮液：有破除平台的低价的办法？](https://xueqiu.com/5582656611/337194653)
+ [BG：投资于“异常值”企业所具备的特点](https://xueqiu.com/2105875935/337180214)
+ [2025年伯克希尔·哈撒韦股东大会（第一部分）](https://xueqiu.com/1173786903/337076455)
